Please assess the completion status of the following clinical trial:

Trial Title: Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced NSCLC~* Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib~* Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment~* Measurable disease~Exclusion Criteria:~* Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment~* Patients who lack of tolerance of erlotinib therapy~* Patients with known brain Metastases~* Patients with demonstrated history of or presence of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).